MAPKi (mitogen‐activated protein kinases ‐MAPKi) that inhibit BRAF (vemurafenib, dabrafenib, encorafenib) have been approved first as single agents before being approved in combination with MEK inhibitors (cobimetinib, trametinib and binimetinib) in metastatic melanoma patients with BRAF V600 mutations.6, 7, 8, 9, 10. Here, BRAF is linked to metastatic melanoma.